SynthesisEuropean heart journal2023
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
Synthesis in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency.Nature medicine · 2025Pooled it
- Impact of Intravenous Iron in patients with heart failure and Iron Deficiency: an updated Meta-analysis of Randomized controlled trials.BMC cardiovascular disorders · 2024Pooled it
- Efficacy of Intravenous Iron in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Systematic Review and Meta-Analysis of Randomized Control Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Impact of anemia on clinical outcomes in patients with acute heart failure: A systematic review and meta-analysis.Clinical cardiology · 2024Pooled it
- Effects of Ferric Derisomaltose in Heart Failure with Iron Deficiency according to Renal Function in the IRONMAN Randomised Controlled Trial.American journal of nephrology · 2026Trial
- Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.European journal of heart failure · 2025Trial
- Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial.European journal of heart failure · 2025Trial
- Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure.Journal of the American College of Cardiology · 2024Trial
- Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.European heart journal · 2024Trial
- The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction.Journal of cardiac failure · 2024Trial
- Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.European heart journal · 2024Trial
- Review
- Prognostic Impact of Cardiorenal Anemia Syndrome in Patients With Atrial Functional Mitral Regurgitation: Subanalysis From REVEAL-AFMR Registry.Circulation reports · 2026Article
- Iron deficiency in primary care patients with heart failure: a cross-sectional study of the heart failure in Southern Sweden (HISS) cohort.BMC cardiovascular disorders · 2026Article
- Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure.Clinical cardiology · 2026Article
- Biomarkers of iron deficiency and prognosis in patients hospitalised with new-onset heart failure and a reduced left ventricular ejection fraction.Open heart · 2026Article
- Iron deficiency and iron supplementation in heart failure: a dynamic phenotype and a moving therapeutic target.ESC heart failure · 2026Article
- Iron deficiency and reduced exercise tolerance in adult Fontan patients.Frontiers in pediatrics · 2026Article
- Ironing out the details: a comprehensive review of iron therapy in heart failure.The British journal of cardiology · 2026Article
- Prognostic Value of Different Iron Status Definitions in Congestive Heart Failure: A Retrospective MIMIC-IV Analysis of Risk Stratification and Mortality.Journal of clinical medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
Abstract
BACKGROUND AND
aimsWhereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinical events remain the subject of research. This meta-analysis aimed to characterize the effects of FCM therapy on hospitalizations and mortality.
methodsPatient-level data from randomized, placebo-controlled FCM trials including adults with HF and iron deficiency with ≥52 weeks follow-up were analysed. The co-primary efficacy endpoints were (i) composite of total/recurrent cardiovascular hospitalizations and cardiovascular death and (ii) composite of total HF hospitalizations and cardiovascular death, through 52 weeks. Key secondary endpoints included individual composite endpoint components. Event rates were analysed using a negative binomial model. Treatment-emergent adverse events were also examined.
resultsThree FCM trials with a total of 4501 patients were included. Ferric carboxymaltose was associated with a significantly reduced risk of co-primary endpoint 1 (rate ratio 0.86; 95% confidence interval 0.75-0.98; P = .029; Cochran Q: 0.008), with a trend towards a reduction of co-primary endpoint 2 (rate ratio 0.87; 95% confidence interval 0.75-1.01; P = .076; Cochran Q: 0.024). Treatment effects appeared to result from reduced hospitalization rates, not improved survival. Treatment appeared to have a good safety profile and was well tolerated.
conclusionsIn iron-deficient patients with HF with reduced left ventricular ejection fraction, intravenous FCM was associated with significantly reduced risk of hospital admissions for HF and cardiovascular causes, with no apparent effect on mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.